Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status.

Riccardo Lobefaro,Giuseppe Viscardi,Raimondo Di Liello,Giacomo Massa,Maria Lucia Iacovino,Francesca Sparano,Roberto Ferrara,Diego Signorelli,Claudia Proto,Arsela Prelaj,Giulia Galli,Alessandro De Toma,Marta Brambilla,Monica Ganzinelli,Benedetta Trevisan,Achille Bottiglieri,Filippo de Braud,Floriana Morgillo,Marina Chiara Garassino,Giuseppe Lo Russo

Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status.

2020

e21601Background: The introduction of Immunotherapy (IO) has dramatically improved the prognosis of patients (pts) with advanced Non-Small Cell Lung Cancer (NSCLC). However, data regarding the role...

Keywords:

Oncology
Lung cancer
non small cell
Internal medicine
Poor performance status
Pathology
Immunotherapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations